Graphical Abstract
Leave this area blank for abstract info.
During HIV-1 replication, the viral RNA genome is reverse transcribed into a double stranded DNA by the virally encoded multifunctional enzyme reverse transcriptase (RT). 1 HIV-1 RT remains a major target for continued development of antagonists to inhibit virus replication and stem the devastating consequences of AIDS.
Two classes of drugs belonging either to the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) or to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been used in the clinic as part of the antiretroviral therapy against HIV/AIDS. 2 NRTIs compete with the natural deoxynucleoside triphosphates (dNTPs) during DNA synthesis and act as chain terminators. 3 In contrast, NNRTIs are noncompetitive inhibitors that bind at an allosteric nonsubstrate binding site, which is distinct from the substrate binding site of HIV-1 RT. 4 While the unique pharmacology of these inhibitors has rendered their use in highly active antiretroviral therapy (HAART) therapy, HIV-1 has the ability to develop drug resistance mutations for both NRTI and NNRTIs. 5 Thus, design of novel lead compounds that can inhibit wild-type and drug resistant HIV-1 RTs is a subject of major interest in anti-HIV research. and linear triphosphate moieties [16] [17] [18] [19] [20] [21] to design modified nucleotides for diverse applications in nucleic acid and antiviral research. 2009 Elsevier Ltd. All rights reserved.
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Negatively-charged nucleotides have limited cellpermeability. Masking the phosphate residues with a lipophilic chain could generate pronucleotides with improved cellular permeability. Prodrugs are chemically modified analogous of the active metabolite that can improve pharmacokinetics and pharmacodynamics (PK/PD) properties of the active drug. However, intracellular chemical transformation needs to be occurred in the presence of different enzymes to convert prodrugs to their corresponding pharmacologically potent compounds in in vivo systems. Prodrug approach offers several advantageous, such as enhancing water solubility, improved chemical stability, decreased toxicity, and insufficient brain penetration. 22 Herein we hypothesized that lipophilic pronucleotides can act as prodrugs of nucleotide analogs.
We have previously reported the synthesis of nucleoside 5′-O-α,β-methylene-β-triphosphates and 5′-O-β,γ-methylenetriphosphates and their potency towards the enzymatic function of wild-type HIV-1 RT. 23, 24 In continuation of our efforts to design a diverse array of modified nucleoside triphosphates as RT inhibitors, we report here the synthesis of β-triphosphotriester pronucleotides (1a− − − −c) of NRTIs, including 3'-fluoro-3'-deoxythymidine (Alovudine, FLT), 2',3'-dideoxy-3'-thiacytidine (Lamivudine, 3TC), and 2',3'-dideoxy-5-fluoro-3'-thiacytidine (Emtricitabine, FTC) (Fig. 1) . To the best of our knowledge, this is the first report of the synthesis of β-triphosphotriester pronucleotides containing two RT inhibitors. To accomplish the synthesis of dendritic β-triphosphotriester pronucleotides, a diffrentially protected 3′-O-TBDMS-2′-deoxythymidine (8) was synthesized according to the previously reported procedures [25] [26] [27] (Scheme 2). In this regard, the 5′-and 3′-hydroxyl groups of 2′-deoxythymidine were protected by tertbutyldimethylsilyl (TBDMS) by the reaction of the unprotected nucleoside with tert-butyldimethylsilyl chloride in the presence of imidazole in DMF. 25, 26 The selective removal of 5′-O-TBDMS group in the presence of AcOH/H 2 O/THF 27 afforded 3′-O-TBDMS-2′-deoxythymidine (8).
Scheme 2. Preparation of 3′-O-TBDMS-2′-deoxythymidine 8.
Our research on the solid-phase synthesis of organophosphorus and organosulfur compounds revealed that the polymer-bound N-Boc p-acetoxybenzyl alcohol (9) is a versatile solid-phase linker system for the phosphorylation of organic compounds 27 . In this regard the polymer-bound N-Boc pacetoxybenzyl alcohol (9) was prepared according to our previously reported procedure 28 and was used as a loading system in this study. Then the polymer-bound N-Boc p-acetoxybenzyl trichloracetimidate (10) was prepared from the reaction of (9) with trichloroacetonitrile in the presence of DBU according to previously reported procedure. 28 Scheme 3 illustrates the synthesis of dendritic nucleoside β-triphosphate analogs (1a− − − −c). The 2'-deoxy TBDMS protected 2′-deoxythymidine (8, 3 mmol) was attached to 10 (1.5 mmol) through 5′-hydroxyl group in the presence of BF 3 .OEt 2 as acidic catalyst 29 to afford 11. The deprotection of 3′-O-TBDMS group in 11 with tetrabutylammonium fluoride (TBAF) in THF afforded (12, ~1.50 mmol), which was divided to three portions (~0.50 mmol each). Each portion of 12 underwent β-triphosphitylation of 3′-hydroxyl group with β-triphosphitylating reagents (6a-c, ~2 mmol, 4 equiv. of 2'-deoxy functions) under extremely dry conditions and nitrogen to afford (13a-c). In this regard, the prepared reaction mixture containing 6a-c in THF (~2 mmol) was added to a swelled solution of polymer-bound N-Boc p-acetoxybenzyl 5′-O-2′-deoxythymidine 12 (~0.50 mmol) and 2,6-lutidine (2 mmol) in anhydrous THF. The mixture was shaken for 28 h with increasing of temperature from -20 °C to room temperature. The resin was collected by filtration, washed with THF and MeOH, respectively, and was dried overnight under vacuum to give 13a-c.
1-Dodecanol was used to mask the negatively-charged cellimpermeable phosphate residues and to improve the lipophilicity of the pronucleotides. Thus, 1-dodecanol (4.0 mmol) and 5-(ethylthio)-1H-tetrazole (4.0 mmol) were added to 13a-c in anhydrous THF. The mixtures were shaken for 24 h at room temperature, then the resins were collected by filtration, washed with DCM and MeOH, respectively, and dried under vacuum to give 14a-c. tert-Butyl hydroperoxide in decane was used for the oxidation of 14a-c to 15a-c. Finally, the cleavage of polymerbound compounds was carried out under acidic conditions (DCM/TFA/H 2 O/1,2-ethanedithiol). The linker-trapped resin 10 was separated from the final products by filtration. After filtration, the solvents were removed using lyophilization and the crude products were purified (>98%) using HPLC system to afford pure 1a-c products in 51-53% overall yield calculated from 10. The chemical structures of the final products (1a−c) were determined by nuclear magnetic resonance spectra ( 1 H NMR, 13 C NMR, and 31 P NMR), SELDI-TOF mass spectrometer, and quantitative phosphorus analysis. Scheme 3. Preparation of pronucleotide derivatives of 3′-fluoro-3′-deoxythymidine, 2',3'-dideoxy-5-fluoro-3'-thiacytidine, and 2',3'-dideoxy-3'-thiacytidine 1a-c.
In conclusion, a polymer-bound N-Boc p-acetoxybenzyl 5′-O-2′-deoxythymidine was reacted with three dinucleoside phosphorochloridites containing FLT, FTC, and 3TC in the presence of 2,6-lutidine in a solid phase reaction. Subsequent conjugation with dodecyl alcohol to mask the negatively charged phosphate in the presence of 5-(ethylthio)-1H-tetrazole, oxidation with tert-butyl hydroperoxide, and acidic cleavage, respectively, afforded the β-triphosphotriester nucleotide derivatives 1a-c containing three different nucleosides and a dodecyl chain. The compounds will be further evaluated for anti-HIV activities.
